Novel Cytocidal Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl) Benzenesulfonates and Benzenesulfonamides with Affinity to the Colchicine-Binding Site: Is the Phenyl 2-Imidazolidinone Moiety a New Haptophore for the Design of New Antimitotics?
Phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs) and phenyl 4-(2-oxoimidazolidin- 1-yl)benzenesulfonamides (PIB-SAs) are new, potent combretastatin A-4 (CA-4) analogs designed on the basis of their common phenyl 2-imidazolidone moiety. This phenyl 2-imidazolidone group is a bioisosteric equivalent of the trimethoxyphenyl group also found in colchicine, podophyllotoxin and several other ligands of the colchicine-binding site (C-BS). In this study, we investigate the interactions involved in the binding of PIB-SO and PIB-SA into the C-BS. We describe three distinct pockets (I, II, and III) as key structural elements involved in the interactions between the C-BS and PIB-SOs as well as PIB-SAs. We show that PIB-SOs and PIB-SAs adopt 4 and 3 distinct binding conformations, respectively, within the C-BS. The binding conformations I and IV are common to most PIB-SOs and PIB-SAs exhibiting high affinity for the C-BS and high cytocidal potency. In addition, binding conformation I is the main conformation adopted by PIB-SOs, PIB-SAs, T138067, ABT-751, colchicine and CA-4. We also observe that the sulfonate and the sulfonamide moieties of PIB-SOs and PIB-SAs are bioisosteric equivalents. Interestingly, we further find that a large portion of the phenyl 2-imidazolidinone moiety in these analogs does not bind to pocket I unlike the trimethoxyphenyl moiety found in several antimicrotubule agents such as colchicine, CA-4 and podophyllotoxin, suggesting that the phenyl 2-imidazolidinone group may represent a new haptophoric moiety useful for the design of new C-BS inhibitors mimicking the tropolone and the methoxylated phenolic moieties of colchicine and CA-4, respectively.
References
[1]
Mariotto, A.B., Yabroff, K.R., Shao, Y.W., Feuer, E.J. and Brown, M.L. (2011) Projections of the Cost of Cancer Care in the United States: 2010-2020. Journal of the National Cancer Institute, 103, 117-128.
http://dx.doi.org/10.1093/jnci/djq495
[2]
Bray, F., Jemal, A., Grey, N., Ferlay, J. and Forman, D. (2012) Global Cancer Transitions According to the Human Development Index (2008-2030): A Population-Based Study. The Lancet Oncology, 13, 790-801.
http://dx.doi.org/10.1016/S1470-2045(12)70211-5
[3]
International Agency for Research on Cancer, Cancer Research UK (2012) World Cancer Factsheet. Cancer Research UK, London.
[4]
American Cancer Society (2015) Cancer Facts & Figures 2015. American Cancer Society, Atlanta.
[5]
Sawyer, T.K. (2004) Cancer Metastasis Therapeutic Targets and Drug Discovery: Emerging Small-Molecule Protein Kinase Inhibitors. Expert Opinion on Investigational Drugs, 13, 1-19.
[6]
Sawyers, C. (2004) Targeted Cancer Therapy. Nature, 432, 294-297. http://dx.doi.org/10.1038/nature03095
[7]
Oslund, K.L., Miller, L.A., Usachenko, J.L., Tyler, N.K., Wu, R. and Hyde, D.M. (2004) Oxidant-Injured Airway Epithelial Cells Upregulate Thioredoxin but Do Not Produce Interleukin-8. American Journal of Respiratory Cell and Molecular Biology, 30, 597-604. http://dx.doi.org/10.1165/rcmb.2002-0273OC
[8]
Tosoni, A., Ermani, M. and Brandes, A.A. (2004) The Pathogenesis and Treatment of Brain Metastases: A Comprehensive Review. Critical Reviews in Oncology/Hematology, 52, 199-215.
http://dx.doi.org/10.1016/j.critrevonc.2004.08.006
[9]
Wolf, M., Tebbe, S. and Fink, T. (2004) First-Line Chemotherapy in Metastatic Small-Cell Lung Cancer (SCLC). Lung Cancer, 45, S223-S234. http://dx.doi.org/10.1016/j.lungcan.2004.07.971
[10]
Pouessel, D., Culine, S., Becht, C., Ychou, M., Romieu, G., Fabbro, M., Cupissol, D. and Pinguet, F. (2004) Gemcitabine and Docetaxel as Front-Line Chemotherapy in Patients with Carcinoma of an Unknown Primary Site. Cancer, 100, 1257-1261. http://dx.doi.org/10.1002/cncr.20100
[11]
Gridelli, C., Rossi, A., Maione, P., Rossi, E., Castaldo, V., Sacco, P.C. and Colantuoni, G. (2009) Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle against Non-Small Cell Lung Cancer. The Oncologist, 14, 612- 620. http://dx.doi.org/10.1634/theoncologist.2008-0287
[12]
Kanthou, C. and Tozer, G.M. (2009) Microtubule Depolymerizing Vascular Disrupting Agents: Novel Therapeutic Agents for Oncology and Other Pathologies. International Journal of Experimental Pathology, 90, 284-294.
http://dx.doi.org/10.1111/j.1365-2613.2009.00651.x
[13]
Patterson, D.M. and Rustin, G.J. (2007) Vascular Damaging Agents. Clinical Oncology (Royal College of Radiologists), 19, 443-456. http://dx.doi.org/10.1016/j.clon.2007.03.014
[14]
Marrelli, M., Conforti, F., Statti, G.A., Cachet, X., Michel, S., Tillequin, F. and Menichini, F. (2011) Biological Potential and Structure-Activity Relationships of Most Recently Developed Vascular Disrupting Agents: An Overview of New Derivatives of Natural Combretastatin A-4. Current Medicinal Chemistry, 18, 3035-3081.
http://dx.doi.org/10.2174/092986711796391642
[15]
Berlin, J.D., Venook, A., Bergsland, E., Rothenberg, M., Lockhart, A.C. and Rosen, L. (2008) Phase II Trial of T138067, a Novel Microtubule Inhibitor, in Patients with Metastatic, Refractory Colorectal Carcinoma. Clinical Colorectal Cancer, 7, 44-47. http://dx.doi.org/10.3816/CCC.2008.n.006
[16]
Meany, H.J., Sackett, D.L., Maris, J.M., Ward, Y., Krivoshik, A., Cohn, S.L., Steinberg, S.M., Balis, F.M. and Fox, E. (2010) Clinical Outcome in Children with Recurrent Neuroblastoma Treated with ABT-751 and Effect of ABT-751 on Proliferation of Neuroblastoma Cell Lines and on Tubulin Polymerization in Vitro. Pediatric Blood & Cancer, 54, 47- 54. http://dx.doi.org/10.1002/pbc.22267
[17]
Tron, G.C., Pirali, T., Sorba, G., Pagliai, F., Busacca, S. and Genazzani, A.A. (2006) Medicinal Chemistry of Combretastatin A4: Present and Future Directions. Journal of Medicinal Chemistry, 49, 3033-3044.
http://dx.doi.org/10.1021/jm0512903
[18]
Nam, N.H. (2003) Combretastatin A-4 Analogues as Antimitotic Antitumor Agents. Current Medicinal Chemistry, 10, 1697-1722. http://dx.doi.org/10.2174/0929867033457151
[19]
Vincent, L., Kermani, P., Young, L.M., Cheng, J., Zhang, F., Shido, K., Lam, G., Bompais-Vincent, H., Zhu, Z., Hicklin, D.J., Bohlen, P., Chaplin, D.J., May, C. and Rafii, S. (2005) Combretastatin A4 Phosphate Induces Rapid Regression of Tumor Neovessels and Growth through Interference with Vascular Endothelial-Cadherin Signaling. The Journal of Clinical Investigation, 115, 2992-3006. http://dx.doi.org/10.1172/JCI24586
[20]
Messaoudi, S., Treguier, B., Hamze, A., Provot, O., Peyrat, J.F., De Losada, J.R., Liu, J.M., Bignon, J., Wdzieczak-Bakala, J., Thoret, S., Dubois, J., Brion, J.D. and Alami, M. (2009) Isocombretastatins A versus Combretastatins A: The Forgotten isoCA-4 Isomer as a Highly Promising Cytotoxic and Antitubulin Agent. Journal of Medicinal Chemistry, 52, 4538-4542. http://dx.doi.org/10.1021/jm900321u
[21]
Chaudhary, A., Pandeya, S.N., Kumar, P., Sharma, P.P., Gupta, S., Soni, N., Verma, K.K. and Bhardwaj, G. (2007) Combretastatin A-4 Analogs as Anticancer Agents. Mini Reviews in Medicinal Chemistry, 7, 1186-1205.
http://dx.doi.org/10.2174/138955707782795647
[22]
Hsieh, H.P., Liou, J.P. and Mahindroo, N. (2005) Pharmaceutical Design of Antimitotic Agents Based on Combretastatins. Current Pharmaceutical Design, 11, 1655-1677. http://dx.doi.org/10.2174/1381612053764751
[23]
Shan, Y., Zhang, J., Liu, Z., Wang, M. and Dong, Y. (2011) Developments of Combretastatin A-4 Derivatives as Anticancer Agents. Current Medicinal Chemistry, 18, 523-538. http://dx.doi.org/10.2174/092986711794480221
[24]
Lu, Y., Chen, J.J., Xiao, M., Li, W. and Miller, D.D. (2012) An Overview of Tubulin Inhibitors that Interact with the Colchicine Binding Site. Pharmaceutical Research, 29, 2943-2971. http://dx.doi.org/10.1007/s11095-012-0828-z
Ducki, S., Mackenzie, G., Greedy, B., Armitage, S., Chabert, J.F., Bennett, E., Nettles, J., Snyder, J.P. and Lawrence, N.J. ( 2009) Combretastatin-Like Chalcones as Inhibitors of Microtubule Polymerisation. Part 2: Structure-Based Discovery of α-Aryl Chalcones. Bioorganic & Medicinal Chemistry, 17, 7711-7722.
[28]
Ducki, S., Rennison, D., Woo, M., Kendall, A., Chabert, J.F., McGown, A.T. and Lawrence, N.J. (2009) Combretastatin-Like Chalcones as Inhibitors of Microtubule Polymerization. Part 1: Synthesis and Biological Evaluation of Antivascular Activity. Bioorganic & Medicinal Chemistry, 17, 7698-7710. http://dx.doi.org/10.1016/j.bmc.2009.09.039
[29]
Wang, L., Woods, K.W., Li, Q., Barr, K.J., McCroskey, R.W., Hannick, S.M., Gherke, L., Credo, R.B., Hui, Y.H., Marsh, K., Warner, R., Lee, J.Y., Zielinski-Mozng, N., Frost, D., Rosenberg, S.H. and Sham, H.L. (2002) Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure-Activity Relationship, Pharmacokinetics, and in Vivo Antitumor Activity Evaluation. Journal of Medicinal Chemistry, 45, 1697-1711.
http://dx.doi.org/10.1021/jm010523x
[30]
Romagnoli, R., Baraldi, P.G., Cruz-Lopez, O., Lopez Cara, C., Carrion, M.D., Brancale, A., Hamel, E., Chen, L., Bortolozzi, R., Basso, G. and Viola, G. (2010) Synthesis and Antitumor Activity of 1,5-Disubstituted 1,2,4-Triazoles as Cis-Restricted Combretastatin Analogues. Journal of Medicinal Chemistry, 53, 4248-4258.
http://dx.doi.org/10.1021/jm100245q
[31]
Akselsen, O.W., Odlo, K., Cheng, J.J., Maccari, G., Botta, M. and Hansen, T.V. (2012) Synthesis, Biological Evaluation and Molecular Modeling of 1,2,3-Triazole Analogs of Combretastatin A-1. Bioorganic & Medicinal Chemistry, 20, 234- 242. http://dx.doi.org/10.1016/j.bmc.2011.11.010
[32]
Kim, Y., Nam, N.H., You, Y.J. and Ahn, B.Z. (2002) Synthesis and Cytotoxicity of 3,4-Diaryl-2(5H)-Furanones. Bioorganic & Medicinal Chemistry Letters, 12, 719-722. http://dx.doi.org/10.1016/S0960-894X(01)00831-9
[33]
Ohsumi, K., Hatanaka, T., Fujita, K., Nakagawa, R., Fukuda, Y., Nihei, Y., Suga, Y., Morinaga, Y., Akiyama, Y. and Tsuji, T. (1998) Syntheses and Antitumor Activity of Cis-Restricted Combretastatins: 5-Membered Heterocyclic Analogues. Bioorganic & Medicinal Chemistry Letters, 8, 3153-3158. http://dx.doi.org/10.1016/S0960-894X(98)00579-4
[34]
Fortin, J.S., Cote, M.-F., Lacroix, J., Desjardins, M., Petitclerc, E. and C.-Gaudreault, R. (2008) Selective Alkylation of βII-Tubulin and Thioredoxin-1 by Structurally Related Subsets of Aryl Chloroethylureas Leading to either Anti-Microtubules or Redox Modulating Agents. Bioorganic & Medicinal Chemistry, 16, 7277-7290.
http://dx.doi.org/10.1016/j.bmc.2008.06.028
[35]
Fortin, J.S., Lacroix, J., Desjardins, M., Patenaude, A., Petitclerc, E. and C.-Gaudreault, R. (2007) Alkylation Potency and Protein Specificity of Aromatic Urea Derivatives and Bioisosteres as Potential Irreversible Antagonists of the Colchicine-Binding Site. Bioorganic & Medicinal Chemistry, 15, 4456-4469. http://dx.doi.org/10.1016/j.bmc.2007.04.028
[36]
Fortin, S., Bouchon, B., Chambon, C., Lacroix, J., Moreau, E., Chezal, J.-M., Degoul, F. and C.-Gaudreault, R. (2011) Characterization of the Covalent Binding of N-Phenyl-N’-(2-chloroethyl)ureas to β-Tubulin: Importance of Glutamic Acid 198 in Microtubule Stability. The Journal of Pharmacology and Experimental Therapeutics, 336, 460-467.
http://dx.doi.org/10.1124/jpet.110.171082
[37]
Fortin, S., Moreau, E., Lacroix, J., Teulade, J.-C., Patenaude, A. and C.-Gaudreault, R. (2007) N-Phenyl-N’-(2-chlo- roethyl)urea Analogues of Combretastatin A-4: Is the N-Phenyl-N’-(2-chloroethyl)urea Pharmacophore Mimicking the Trimethoxy Phenyl Moiety? Bioorganic & Medicinal Chemistry Letters, 17, 2000-2004.
http://dx.doi.org/10.1016/j.bmcl.2007.01.023
[38]
Fortin, S., Moreau, E., Patenaude, A., Desjardins, M., Lacroix, J., Rousseau, J.L. and C.-Gaudreault, R. (2007) N-Phenyl-N’-(2-chloroethyl)ureas (CEU) as Potential Antineoplastic Agents. Part 2: Role of ω-Hydroxyl Group in the Covalent Binding to β-Tubulin. Bioorganic & Medicinal Chemistry, 15, 1430-1438.
http://dx.doi.org/10.1016/j.bmc.2006.11.005
[39]
Fortin, S., Wei, L., Moreau, E., Labrie, P., Petitclerc, E., Kotra, L.P. and C.-Gaudreault, R. (2009) Mechanism of Action of N-Phenyl-N’-(2-chloroethyl)ureas in the Colchicine-Binding Site at the Interface between α- and β-Tubulin. Bioorganic & Medicinal Chemistry, 17, 3690-3697. http://dx.doi.org/10.1016/j.bmc.2009.03.056
[40]
Fortin, S., Labrie, P., Moreau, E., Wei, L., Kotra, L.P. and C.-Gaudreault, R. (2008) A Comparative Molecular Field and Comparative Molecular Similarity Indices Analyses (CoMFA and CoMSIA) of N-Phenyl-N’-(2-chloroethyl)ureas Targeting the Colchicine-Binding Site as Anticancer Agents. Bioorganic & Medicinal Chemistry, 16, 1914-1926.
http://dx.doi.org/10.1016/j.bmc.2007.11.004
[41]
Moreau, E., Fortin, S., Desjardins, M., Rousseau, J.L., Petitclerc, E. and C.-Gaudreault, R. (2005) Optimized N-Phenyl-N’-(2-chloroethyl)ureas as Potential Antineoplastic Agents: Synthesis and Growth Inhibition Activity. Bioorganic & Medicinal Chemistry, 13, 6703-6712. http://dx.doi.org/10.1016/j.bmc.2005.07.048
[42]
Moreau, E., Fortin, S., Lacroix, J., Patenaude, A., Rousseau, J.L. and C.-Gaudreault, R. (2008) N-Phenyl-N’- (2-chloroethyl)ureas (CEUs) as Potential Antineoplastic Agents. Part 3: Role of Carbonyl Groups in the Covalent Binding to the Colchicine-Binding Site. Bioorganic & Medicinal Chemistry, 16, 1206-1217.
http://dx.doi.org/10.1016/j.bmc.2007.10.078
[43]
Fortin, S., Wei, L., Moreau, E., Lacroix, J., Co?te?, M.-F., Petitclerc, E., Kotra, L.P. and C.-Gaudreault, R. (2011) Design, Synthesis, Biological Evaluation, and Structure-Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1- yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4. Journal of Medicinal Chemistry, 54, 4559-4580. http://dx.doi.org/10.1021/jm200488a
[44]
Fortin, S., Wei, L., Moreau, E., Lacroix, J., Cote, M.-F., Petitclerc, E., Kotra, L.P. and C.-Gaudreault, R. (2011) Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonamides as Antimitotics. Antiproliferative, Antiangiogenic and Antitumoral Activity, and Quantitative Structure-Activity Relationships. European Journal of Medicinal Chemistry, 46, 5327-5342. http://dx.doi.org/10.1016/j.ejmech.2011.08.034
[45]
Ruppert, J., Welch, W. and Jain, A.N. (1997) Automatic Identification and Representation of Protein Binding Sites for Molecular Docking. Protein Science, 6, 524-533. http://dx.doi.org/10.1002/pro.5560060302
[46]
Dorleans, A., Gigant, B., Ravelli, R.B., Mailliet, P., Mikol, V. and Knossow, M. (2009) Variations in the Colchicine- Binding Domain Provide Insight into the Structural Switch of Tubulin. Proceedings of the National Academy of Sciences of the United States of America, 106, 13775-13779. http://dx.doi.org/10.1073/pnas.0904223106
[47]
Ravelli, R.B., Gigant, B., Curmi, P.A., Jourdain, I., Lachkar, S., Sobel, A. and Knossow, M. (2004) Insight into Tubulin Regulation from a Complex with Colchicine and a Stathmin-Like Domain. Nature, 428, 198-202.
http://dx.doi.org/10.1038/nature02393
[48]
Nguyen, T.L., McGrath, C., Hermone, A.R., Burnett, J.C., Zaharevitz, D.W., Day, B.W., Wipf, P., Hamel, E. and Gussio, R. (2005) A Common Pharmacophore for a Diverse Set of Colchicine Site Inhibitors Using a Structure-Based Approach. Journal of Medicinal Chemistry, 48, 6107-6116. http://dx.doi.org/10.1021/jm050502t
[49]
Tripathi, A., Durrant, D., Lee, R.M., Baruchello, R., Romagnoli, R., Simoni, D. and Kellogg, G.E. (2009) Hydropathic Analysis and Biological Evaluation of Stilbene Derivatives as Colchicine Site Microtubule Inhibitors with Anti-Leukemic Activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 24, 1237-1244.
http://dx.doi.org/10.3109/14756360902787055
[50]
Hu, L., Li, Z.R., Li, Y., Qu, J., Ling, Y.H., Jiang, J.D. and Boykin, D.W. (2006) Synthesis and Structure-Activity Relationships of Carbazole Sulfonamides as a Novel Class of Antimitotic Agents against Solid Tumors. Journal of Medicinal Chemistry, 49, 6273-6282. http://dx.doi.org/10.1021/jm060546h
[51]
Zhou, J., Zhang, Y., Cui, Y.W., Li, Z.M., Song, H.R., Dong, J.H., Chen, X.G. and Xu, B.L. (2011) Synthesis and Cytotoxic Evaluation of N-(4-Methoxy-1H-benzo[d]imidazol-7-yl)-arylsulfonamide and N-Aryl-(4-methoxy-1H-benzo [d]imi- dazol)-7-sulfonamide Analogs of Combretastatin A-4. Journal of Asian Natural Products Research, 13, 330-340.
http://dx.doi.org/10.1080/10286020.2011.556091
[52]
SYBYL. 8.1, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.
